SEC Form 4 · accession 0001209191-17-053004
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ulrik B. Nielsen
Director
Period of report
Sep 13, 2017
Accepted (ET)
Sep 15, 2017 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2017 | M | 100 | $13.20 | A | 22,781 | D | |
| Common Stock | Sep 14, 2017 | S | 100 | $14.20 | D | 22,681 | D | |
| Common Stock | Sep 15, 2017 | M | 7,133 | $13.20 | A | 29,814 | D | |
| Common Stock | Sep 15, 2017 | M | 663 | $13.20 | A | 30,477 | D | |
| Common Stock | Sep 15, 2017 | S | 7,796 | $14.23 | D | 22,681 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.99 | Sep 13, 2017 | A | 7,500 | A | — | Sep 12, 2027 | Common Stock | 7,500 | 7,500 | D |
| Stock Option (right to buy)F1 | $13.20 | Sep 14, 2017 | M | 100 | D | — | Oct 4, 2017 | Common Stock | 100 | 7,133 | D |
| Stock Option (right to buy)F1 | $13.20 | Sep 15, 2017 | M | 7,133 | D | — | Oct 4, 2017 | Common Stock | 7,133 | 0 | D |
| Stock Option (right to buy)F2,F1 | $13.20 | Sep 15, 2017 | M | 663 | D | — | Oct 4, 2017 | Common Stock | 663 | 0 | D |
Explanation of responses
- F1This option is fully vested.
- F2This option was previously reported as covering 3,378 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.